Business Development


We are committed to strategic growth through targeted product acquisition. The company actively pursues product/program purchase, in-licensing, and co-development opportunities that are aligned with its internal areas of expertise and offer significant value to its pipeline.


Elisabeth Leiderman, MD
Checkpoint Therapeutics, Inc.
2 Gansevoort Street
9th Floor
New York, NY 10014